IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Responses Against Colon Cancer
Li, Yi1,4; Zeng, Hui2,3,5; Xu, Ren-He2,3; Liu, Bei1,2; Li, Zihai1,2
关键词Embryonic stem cells Induced pluripotent stem cells Cancer vaccine Oncofetal antigen Myeloid-derived suppressor cells
刊名STEM CELLS
2009-12-01
DOI10.1002/stem.234
27期:12页:3103-3111
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cell & Tissue Engineering ; Biotechnology & Applied Microbiology ; Oncology ; Cell Biology ; Hematology
研究领域[WOS]Cell Biology ; Biotechnology & Applied Microbiology ; Oncology ; Hematology
关键词[WOS]HEAT-SHOCK PROTEINS ; HUMAN SOMATIC-CELLS ; REGULATORY T-CELLS ; SUPPRESSOR-CELLS ; FETAL ANTIGENS ; DIRECTED DIFFERENTIATION ; CANCER/TESTIS ANTIGENS ; HUMAN BLASTOCYSTS ; DENDRITIC CELLS ; MURINE SARCOMAS
英文摘要

The history of immunizing with embryonic materials to generate an antitumor immune response dates back to a century ago. The premise is that cancer cells share the expression of oncofetal antigens with embryonic materials and that the immune response against these antigens in the embryonic tissues is cross-protective against cancer. However, such a practice has never advanced beyond experimental animal settings, because of lack of uniformed source tissues and ethical challenges. With the availability of well-characterized human pluripotent stem cells, it is now possible to ask whether tumor protective immunity could indeed be elicited with stem cells. Herein, we investigated whether vaccination with defined human embryonic stem cells (hESCs) or induced pluripotent stem (iPS) cells was effective against a colon carcinoma. We discovered that vaccination of mice with hESC line H9 generated consistent cellular and humoral immune responses against CT26 colon carcinoma. Protection correlated strongly with the expansion of tumor-responsive and interferon-c-producing cells and the profound loss of CD11b(+)Gr-1(+) myeloid-derived suppressor cells in the spleen. No evidence of autoimmunity was observed. We also compared the immunogenicity against colon cancer between a hESC line CT2 and an iPS cell line TZ1 that were generated in the same stem cell facility. We found that the iPS cell line was inferior to the hESC line in conferring tumor protection, suggesting that there is heterogeneity of expression of oncofetal antigens by hESCs and iPS cells. We conclude that the hESC-based vaccine is a promising modality for immunotherapy of cancer. STEM CELLS 2009;27:3103-3111

语种英语
WOS记录号WOS:000273569800023
项目编号06SCA031 ; 06SCD02
资助机构Connecticut Stem Cell Research Grants Program
引用统计
被引频次:30[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58984
专题北京大学第二临床医学院
作者单位1.Univ Connecticut, Sch Med, Dept Immunol, Farmington, CT 06030 USA
2.Univ Connecticut, Sch Med, UConn Stem Cell Inst, Farmington, CT 06030 USA
3.Univ Connecticut, Sch Med, Dept Genet & Dev Biol, Farmington, CT 06030 USA
4.Peking Univ, Peoples Hosp, Dept Gynecol & Obstet, Beijing 100871, Peoples R China
5.Cent S Univ, Dept Hematol, Xiang Ya Hosp, Changsha, Hunan, Peoples R China
推荐引用方式
GB/T 7714
Li, Yi,Zeng, Hui,Xu, Ren-He,et al. Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Responses Against Colon Cancer[J]. STEM CELLS,2009,27(12):3103-3111.
APA Li, Yi,Zeng, Hui,Xu, Ren-He,Liu, Bei,&Li, Zihai.(2009).Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Responses Against Colon Cancer.STEM CELLS,27(12),3103-3111.
MLA Li, Yi,et al."Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Responses Against Colon Cancer".STEM CELLS 27.12(2009):3103-3111.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Yi]的文章
[Zeng, Hui]的文章
[Xu, Ren-He]的文章
百度学术
百度学术中相似的文章
[Li, Yi]的文章
[Zeng, Hui]的文章
[Xu, Ren-He]的文章
必应学术
必应学术中相似的文章
[Li, Yi]的文章
[Zeng, Hui]的文章
[Xu, Ren-He]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。